Viewing data from:

VINBLASTINE SULFATE

ANDA

VINBLASTINE SULFATE | A089011 | ABRAXIS PHARMACEUTICAL PRODUCTS

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Vinblastine Sulfate (2023)

Total Spending

$3K

Total Claims

Beneficiaries

Avg Cost/Unit

$4.22

Spending Trend

$5K(2019)→$4K(2020)→$5K(2021)→$4K(2022)→$3K(2023)

YoY Change:-4.3%

5yr CAGR:+4.0%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Medicare Part B Spending

CMS physician-administered drug spending for Vinblastine Sulfate (2023)

Total Spending

$93K

Total Claims

2,426

Beneficiaries

453

ASP Price

—

HCPCS: J9360 — Injection, vinblastine sulfate, 1 mg

Source: CMS Medicare Part B Spending by Drug (2023). Shows physician-administered drug costs.

API Supply Chain3 active DMFs3 inactive

2 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

MINAKEM HIGH POTENTVINBLASTINE SULFATE

DMF 53351984

HUBEI HONCH PHARMACEUTICAL CO LTDVINBLASTINE SULFATE PHARMACEUTICAL INTERMEDATE

DMF 392642024

HUBEI HONCH PHARMACEUTICAL CO LTDVINBLASTINE SULFATE NON-STERILE, BULK DRUG SUBSTANCE

DMF 399442025

CIPLA LTDInactiveVINBLASTINE SULFATE USP

DMF 64991986

ADITHYA ALKALOIDS LTDInactiveVINBLASTINE SULFATE

DMF 112841995

ZHEJIANG HISUN PHARMACEUTICAL CO LTDInactiveVINBLASTINE SULFATE USP

DMF 162402002

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 10MG/VIAL

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Nov 18, 1985

No patent or exclusivity listings for this strength.